Kimberly-Clark Completes Acquisition of Kenvue, Creating the Preeminent Global Consumer Health and Wellness Leader
The cash-and-stock deal brings 10 billion-dollar brands together and keeps $2.1 billion in expected run-rate synergies on track, the company said.
- On Monday, November 2, 2026, Kimberly-Clark Corporation completed its acquisition of Kenvue, uniting portfolios of iconic brands including Huggies, Kleenex, Tylenol, and Listerine to create a global consumer health powerhouse.
- Kimberly-Clark announced the deal last year, offering $3.50 in cash and 0.14625 shares per Kenvue share, targeting the global health and wellness market, which exceeds $500 billion in annual spending.
- Following the close, Kimberly-Clark appointed Jonathan Halvorson as chief marketing officer and expanded its board to 13 directors, while reaffirming $2.1 billion in anticipated run-rate synergies within three years.
- Okta will replace Kenvue in the S&P 500 effective before trading opens Wednesday, November 4, 2026, requiring index funds to purchase Okta shares while divesting Kenvue holdings.
- CEO Mike Hsu pledged to maintain Kimberly-Clark's 'dividend king' status, stating, "We believe we're going to create generational value creation on shareholder friendly terms." The company aims to deliver this through strategic integration.
12 Articles
12 Articles
Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.
Key PointsThat's expensive, but the tie-up is complementary in several ways.The buyer is also likely to find a way of keeping its Dividend King status alive.10 stocks we like better than Kimberly-Clark › On Monday, one of the largest acquisitions of 2026 closed, almost one year to the day after it was first announced. This is Kimberly-Clark's (NASDAQ:KMB) purchase of consumer healthcare company Kenvue. The two companies said in their original an…
Kimberly-Clark closes $48.7 Kenvue deal, Mark Cuban invests in Dallas startup
Kimberly-Clark has closed its $48.7 billion buyout of Tylenol maker Kenvue while Mark Cuban participated in a $4 million seed funding round for a Dallas-based artificial intelligence startup. Also, an Addison-based company raised $150 million at a valuation of more than $1.4 billion. Read on to learn more about these deals.
Kenvue Is Leaving the S&P 500: Here's What It Means for Investors
Kimberly-Clark is absorbing one of the most recognizable brand portfolios in consumer health, and the deal reshapes what investors own across three different indexes at once. What happens to your dividend income and share value depends on a closing date nobody has announced yet.
Kimberly-Clark Completes Acquisition of Kenvue, Creating the Preeminent Global Consumer Health and Wellness Leader
/PRNewswire/ -- Kimberly-Clark Corporation ("Kimberly-Clark" or "the Company") (NASDAQ: KMB), a core S&P 500 component, today announced that it has completed...
Coverage Details
Bias Distribution
- 83% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
